Capricor Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
11/08/2025 22:01
Capricor Therapeutics Inc CAPR.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of ten analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -52 cents to -42 cents per share. Reported revenue was zero; analysts expected $778.00 thousand. Capricor Therapeutics Inc's reported EPS for the quarter was a loss of 57 cents. The company reported a quarterly loss of $25.91 million. Capricor Therapeutics Inc shares had fallen by 8.7% this quarter and lost 34.3% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 45.8% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Capricor Therapeutics Inc is $21.50, about 57.8% above its last closing price of $9.07 This summary was machine generated from LSEG data August 11 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.47 | -0.57 | Missed |
| Mar. 31 2025 | -0.32 | -0.53 | Missed |
| Dec. 31 2024 | -0.26 | -0.16 | Beat |
| Sep. 30 2024 | -0.36 | -0.38 | Missed |